Rx Nations (Premier Pharmacy Labs, Inc.), Weeki Wachee, FL

Is Rx Nations (Premier Pharmacy Labs, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does Rx Nations (Premier Pharmacy Labs, Inc.) hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH16920 for PREMIER PHARMACY LABS, INC., WEEKI WACHEE, status Closed and PH27284 for PREMIER PHARMACY LABS, INC, WEEKI WACHEE, status Closed. The Colorado State Board of Pharmacy also lists nonresident license OSP 5785 for Premier Pharmacy Labs Inc., Weeki Wachee, FL, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054017536 for PREMIER PHARMACY LABS INC, WEEKI WACHEE, FL, status NOT RENEWED and license 054020918 for PREMIER PHARMACY LABS INC, WEEKI WACHEE, FL, status NOT RENEWED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002378 for PREMIER PHARMACY LABS INC, WEEKI WACHEE, FL, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001157 for Premier Pharmacy Labs Inc, Weeki Wachee, FL, status Closed and license AA-0000053 for Premier Pharmacy Labs Inc, Weeki Wachee, FL, status Closed, as of Nov 10, 2026.

Has Rx Nations (Premier Pharmacy Labs, Inc.) had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Jul 25, 2019) for Rx Nations (Premier Pharmacy Labs, Inc.). State board actions: no Florida Board of Pharmacy action on licenses PH16920 and PH27284 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Premier Pharmacy Labs, Inc.; Rx Nations
Location
Weeki Wachee, FL
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 17, 2021
FDA Data Dashboard inspections
3 inspections: 3 OAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 16 observations
State board records
License found: PH16920, Closed; PH27284, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Premier Pharmacy Labs, Inc., (dba Rx Nations), a 503A facility, with 3 dated actions.

Document
Sep 17, 2021Press release or statementFDA Press Release : Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture and Distribution of Drugs Due to Insanitary Conditions (09/17/2021)FDA copy (archived)
Jul 25, 2019Amended Form 483Second Amended 483 Issued 07/25/2019FDA copy (archived)
Jun 18, 2019Recall noticeFirm Press Release : Premier Pharmacy Labs Issues Voluntary Nationwide Recall of all Unexpired Sterile Drug Product Lots Due to Lack of Sterility Assurance (06/18/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Premier Pharmacy Labs Inc, Weeki Wachee, FL (FEI number 3007271263), matched to this page by exact name, city and state. It lists 3 inspections: 3 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 12, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30072712631092705
Jun 13, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3007271263975321
May 9, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3007271263879640

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 16 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 12, 2019: 16 observations

Firm on the cover
Premier Pharmacy Labs Inc, 8265 Commercial Way, Weeki Wachee, FL 34613-4511
FEI number
3007271263
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically,

A. Your firm failed to investigate the potential sources or causes of particles, fibers, and other defects observed during the visual inspection of finished drug products that were intended to be sterile. A review of the particulate rejection logs from 2019 showed at least <Redacted B4> out of <Redacted B4> batches were identified with over <Redacted B4> units rejected due to cracks, leaks, fibers, or other defects. Examples include:

Drug Product

Lot number

Batc

Rejected Units

Defect Type

Units Distributed

h Size

ORP031119KMSECASUC0307 19SVEC

lli'• r,•• I to I fibers

Orphenadrine Citrate 30mg/ml lml sterile single dose syringe Succinylcholine Chloride 20mg/ml sterile syringe

out of <Redacted B4> units released <Redacted B4> units distributed out of <Redacted B4> units released <Redacted B4> units distributed

[OJIUI

black speck; foreign object cracks; leaking black speck; foreign object

AM ENDMENT2

Succinylcholine Chloride

cracks; leaking

umts released

ma

20mg/ml sterile

black speck; foreign object

units distributed

syringe

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

(1) HEPA filters in ISO 5 hoods used to prepare drug products purported to be sterile appeared to be visibly stained. On 05/01/2019, I (JEK) observed the preparation of the drug product bulk orphendrine citrate 30 mg/ml lot <Redacted B4> and the sterile sub-lots <Redacted B4> and <Redacted B4> in Hood <Redacted B4> in cleanroom (CR <Redacted B4>. The HEPA filter in <Redacted B4> appeared to have stains and discoloration. I (JEK) also observed what appeared to be stains on the HEPA filter in Hood <Redacted B4> in cleanroom <Redacted B4>

(2) During production of orphenadrine citrate 30mg/ml bulk lot <Redacted B4> and sub-lots <Redacted B4> and <Redacted B4> I (JEK) observed open air vents between CR <Redacted B4> and unclassified sterile preparation area. I (JEK) also observed open vents in ISO 7 cleanrooms <Redacted B4> and <Redacted B4> that opened to unclassified areas. These vents were not appropriate for their intended use. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

(1) Vials filled with drug product s that ar e intended to be sterile and stoppered on the <Redacted B4> machine are moved from the ISO 5 area into the ISO 7 clean room (CR <Redacted B4> for capping and crimping. The stoppering arm on the <Redacted B4> machine broke on 11/26/2018 and was not repaired until 01/24/2019. Batches filled on the <Redacted B4> during this time were <Redacted B4> stoppered. There are no controls in place to ensure <Redacted B4> applied stoppers are fully seated before the vials are transferred to the ISO 7 cleanroom. Caps are <Redacted B4> applied to filled stoppered vials <Redacted B4>. The caps are crimped using a non-sterile tool. Examples of product lots filled on the <Redacted B4> between 12/2018 and 01/2019 include: Lot SOD121118SVV A sodium bicarbonate 8.4 % for injection Lot SOD121218.£¥IJVA sodium bicarbonate 8.4 % for injection Lot SOD121318SVVA sodium bicarbonate 8.4 % for injection

(2) Media fill batch records do not include documentation of all interventions performed. ...

Read the full 483 (PDF on fda.gov)

Observation 4

AMENDMENT2

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

(2) Vendor Qualification of suppliers is deficient. SOP for vendor qualification does not include a complete supplier qualification program and there is no requirement to verify evidence obtained in the questionnaire.

(3) Your Quality Unit failed to establish a specification for air velocity for air passing through HEP A filters in the Lamimar Airflow Hoods and in the cleanrooms. All smoke studies have not been received or evaluated that were performed in 2/2019. These were also not evaluated at the time performed.

Observation 5

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, on 2/28/2019, your prepared the sterile drug product 550 ml in ON-Q pump bupivacaine 0.125% (125 mg/ml) preservative free for injection with the beyond use date of 3/9/2019 lot BUP022819NREC to fill the prescriptions for one pump and <Redacted B4> also for one pump to be used as a pain block for shoulder athroscopy. There were no tests performed for sterility and endotoxins and no visual check for particles. These sterile prepared drugs were distributed to patients for use on 2/28/2019. In addition to not performing this testing viable particle environmental monitoring performed at the time of this batch preparation in the clean room <Redacted B4> ISO 5 hood recovered a colong of mold later identified as Engyodontium album by your contract test lab.

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

AM ENDMENT2

Specifically,

(1) Your firm does not continuously monitor differential pressure between classified rooms or between classified and unclassified areas. On 05/24/2019 a magnahelic gauge was installed to permit measurement of the differential pressure between the ISO 7 cleanroom <Redacted B4> CR <Redacted B4> and the ISO 8 anteroom (gowning room). There is no gauge to monitor differential pressure between the ISO 5 zone and the ISO 7 cleanroom <Redacted B4> There is no alarm system to alert operators if the differential pressure cascade is out of specification.

(2) Non-viable particle counts in the ISO 7 cleanrooms are measured <Redacted B4>

Observation 7

Aseptic processing areas are deficient in that floors, walls and ceilings are not smooth and/or hard surfaces that are easily cleanable.

Specifically,

(1) A wall in the hazardous chemical preparation room adjacent to biosafety cabinet <Redacted B4> BSC <Redacted B4> appears to be constructed of cinder block.

(2) The door between the hazardous chemical preparation room and cleanroorn <Redacted B4> is constructed of wood and painted with epoxy paint.

(3) The door between the unclassified buffer room and ISO 8 anteroom (gowning room) is constructed of wood and painted with epoxy paint.

(4) On 05/01/2019, I (JEK) observed that the ceiling tiles in cleanroom <Redacted B4> (CR <Redacted B4> were not flush and were not caulked.

AMENDMENT 2

Observation 8

Aseptic processing areas are deficient regarding temperature and humidity controls.

Specifically, according to the logs used to record temperature, percent relative humidity and differential pressure, the specification for relative humidity in the cleanroom is <Redacted B4>. Such a high level of humidity is not suitable for cleanroom environments.

Sodium Bicarbonate 8.4% lot SOD032819SVEC was filled on the <Redacted B4> on 03/28/2019 in cleanroom <Redacted B4> The batch record showed that the humidity level at the start of filling was 65%. A review of the pressure, temperature, and humidity log showed that on 05/13/2019, the relative humidity measured in cleanroom <Redacted B4> was 68%.

Observation 9

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

A. On 5/1/2019, during the processing of the bulk in-process non-sterile orphenadrine citrate 30 mg/ml for injection lot <Redacted B4> in cleanroom <Redacted B4> I (JEK) observed that the bulk drug substance orphenadrine citrate USP lot <Redacted B4> was mixed with sterile water for injection using in-house reusable depyrogenated glassware <Redacted B4> beakers) and reusable stir bars. I (JEK) observed the use of a <Redacted B4> that was directly placed into the <Redacted B4> beaker containing the in process orphenadrine citrate for pH adjustments. This <Redacted B4> was not dedicated to this product and may be used with other bulk non-sterile substances. I (JEK) also observed the use of a squeeze bottle that was not cleaned sterilized, or depyrogenated that was used to rinse off the <Redacted B4> prior to placing it into the <Redacted B4> beaker containing the in process orphenadrine citrate bulk non-sterile drug. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

tem f

Specifically, bioburden tests performed by your contract test la b u se d <Redacted B4 > as the sa mple si ze dr awn f rom a <Redac ted B4> bul k non- sterile in p rocess ba tc h of m orph ine sulp hate 2 mg/ml lot <Redacted B4> to test for bio burden in accordance w ith <USP 61 > as list ed on the COA and t he contract test lab SOP 451 .1 Microbiolog ica

l Examinat ion of Non sterile II Products: Microbial Enumeration Tests. The sample size requ ired by these test methods are <Redacted B4> or <Redacted B4>

A steril e <R edac ted B 4> sub-lot ( of the bu lk non-st er ile mo rphi ne sulphate 2 mg/ml lot <Redacted B4> l isted above) of morphine sulfate 2 mg/m l lot MOR032318LMDSC was used to dose <R edacted B4> syringes o n 3/27/ 2 018 and

a sample of <Redac ...

Read the full 483 (PDF on fda.gov)

Observation 11

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

AM ENDMENT2

Specifically,

(1) According to procedure 340.7 entitled Cleaning, Use, and Maintenance of the <Redacted B4> Vial Filling System, effective 03/11/2019, section 7.3.2 and 7.4.5, the <Redacted B4> used to fill drug products intended to be sterile into vials is not cleaned using a sporicidal agent..

(2) The <Redacted B4> separating the ISO 5 area from the ISO 7 cleanroom <Redacted B4> CR <Redacted B4> are cleaned with <Redacted B4> sporicidal agent and <Redacted B4>

(3) Multipacks of sterile wipes are opened in the ISO 7 room, completely unwrapped, and placed in a PETG (polyethylene terephthalate glycol) open plastic container in the ISO 7 cleanrooms. These wipes are used to clean the interior of the ISO 5 LAF hoods and the ISO 5 biosafety cabinet. This is a repeat observation from the 2014 inspection.

Observation 12

Results of stability testing are not used in determining appropriate storage conditions and expiration dates.

Specifically,

A. Your firm failed to complete stability studies to support the BUD for drug products intended to be sterile. For example, stability studies have not been completed for the following drug products which are labeled to be stored at room temperature: This is a repeat observation from the 2016 inspection.

Product

BUD

Chlomromazine HCl 25mg/ml 1ml in a 5ml single dose vial

180 davs

AM ENDMENT2

Ephedrine Sulfate 1 0mg/ml preservative free 5ml in a 6ml syringe

60 days

90 days

180 da ys

150 da ys

This is a repeat observation from the 2016 inspection.

B. Your firm reprocessed drug products if these products were not expected to maintain acceptable potency levels through the end of the established beyond use date (BUD). For example, on 11/09/2018, Cyanocobalamin (Vitamin B-12) l000mcg/ml solution lot CYA110918NRVA was initially formulated with <Redacted B4> of cyanocobalamin in 33000ml <Redacted B4> and benzyl alcohol) and had a measured potency of 97.2%. The potency specification is <Redacted B4> for cyanocobalamin 1000mcg/ml and the established BUD is 180 days. ...

Read the full 483 (PDF on fda.gov)

Observation 13

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purported are represented to possess.

AMENDMENT 2

Specifically, your firm has not completed product-specific process validation for drug products including Bupivacaine 0.125%, Succinylcholine Chloride 20mg/ml in 5ml or 10ml single dose syringes, and Cyanocobalamin (Vitamin B-12) I000mcg/ml, and Potassium Chloride 2mEq/ml. There is no assurance that these products are being prepared using a process that consistently delivers products meeting established specifications.

Observation 14

You produced highly potent drugs without providing adequate containment, segregation, cleaning of work surfaces, cleaning of utensils and cleaning of personnel to prevent cross-contamination.

Specifically, highly potent non-sterile drug products containing hormones including testosterone, estradiol, estriol, and progesterone are prepared in the same <Redacted B4> hood where non-potent non-sterile drug products are produced. The <Redacted B4> hood is cleaned with sterile <Redacted B4> batches.

Observation 15

The container labels of your outsourcing facility's drug products are deficient.

1. The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(I0)(A). Specifically, the following information is not found on your some of your drug product labels:

a) the dosage form information is not found on some of your drug product labels. Examples of your drug product labels that do not contain this information: Isoproterenol HCL in D5W, 200mcg/50mL Succinylcholine Chloride 20mg/ml

AMENDMENT2

b) The National Drug Code number, if available; Examples of your drug product labels that do not contain this information: Estriol 1 mg/ml vaginal cream Estradiol 0.3 mg capsules Topiramate 25 mg capsules Ursodiol 100 mg/ml suspension Gabapentin 100 mg/ml suspension

2. The containers of your outsourcing facility's drug products does not include information required by section 503B(a)(l0)(B). Specifically, your containers do not include the following information:

a) Route of administrntion. ...

Read the full 483 (PDF on fda.gov)

Observation 16

AMENDMENT2

1. You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2). Specifically, you compound drug products that: a) are identical or nearly identical to an approved drug that is not on the mug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing; and/ or b) are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug. Examples of compounded drug products that are essentially a copy of one or more approved drugs include: Neostigmine Methlysulfate Inj. lmg/ml Succinylcholine Chloride 20mg/ml

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH16920PharmacyPREMIER PHARMACY LABS, INC.WEEKI WACHEEClosed
PH27284PharmacyPREMIER PHARMACY LABS, INCWEEKI WACHEEClosed

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5785OSPPremier Pharmacy Labs Inc.Weeki Wachee, FLExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054017536LICENSED PHARMACYPREMIER PHARMACY LABS INCWEEKI WACHEE, FLNOT RENEWED
054020918LICENSED PHARMACYPREMIER PHARMACY LABS INCWEEKI WACHEE, FLNOT RENEWED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002378NONRESIDENT PHARMACYPREMIER PHARMACY LABS INCWEEKI WACHEE, FLINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001157Non Resident PharmacyPremier Pharmacy Labs IncWeeki Wachee, FLClosed
AA-0000053Outsourcing Facility-PharmacyPremier Pharmacy Labs IncWeeki Wachee, FLClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.